Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes

Abstract excerpt

PARP inhibitors (PARPis) were initially developed as DNA repair inhibitors that inhibit the catalytic activity of PARP1 and PARP2 and are expected to induce synthetic lethality in BRCA- or homologous recombination (HR)-deficient tumors. However, the clinical indications for PARPis are not necessarily limited to BRCA mutations or HR deficiency; BRCA wild-type and HR-proficient cancers can also derive some benefit...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Integrated Circuits and Semiconductor Failure Analysis
• Share to PARP inhibition in cancer therapy
• Share to Toxin Mechanisms and Immunotoxins